Aktuellt
SENASTE
Redeye leaves its comments on Idogen following the report for the first quarter of 2022. Company operations are centered around phase l/lla-trial start, and patient enrollment in Sweden is estimated to commence mid-year. Meanwhile, the share is currently trading at a single-digit EV.
LÄS MER
